Within the group of spondyloarthropathies patient classification may be based on either the precise diagnosis-for example, ankylosing spondylitis, psoriatic arthritis-or the clinical presentation of the disease (axial disease, articular peripheral disease, enthesiopathic lesions, extra-articular symptoms). The monitoring and treatment of these diseases are related more to their clinical presentation than to their precise diagnosis. 5 Sulphasalazine was developed and manufactured to cure rheumatoid arthritis by eliminating the putative cause, a group B streptococcal intestinal infection. After a temporary demise sulphasalazine gained a position as a second line disease modifying drug mainly through the work of McConkey et al. 6 Sulphasalazine has been acccepted as the drug of choice in the treatment of inflammatory bowel disease.7 Although the stimulus for using sulphasalazine in the treatment of spondyloarthropathy did not derive directly from its use in patients with rheumatoid arthritis, there are several arguments for considering it: (a) the common association between inflammatory bowel disease and spondyloarthropathy2; (b) the description of inflammatory lesions in the ileum of patients with spondyloarthropathy;8 9 and (c) the reported association between disturbances in bowel flora and ankylosing spondylitis.' Much of the rationale postdated the early clinical studies. " Since 1984 a number of workers have shown that sulphasalazine may be effective in the treatment of spondyloarthropathies. Meta-analysis carried out on five randomised controlled trials'2-'6 suggests that sulphasalazine is a safe and effective drug in the short term (three to six months) treatment of ankylosing spondylitis. '7 Other studies suggest that a beneficial effect of sulphasalazine might be observed not only in ankylosing spondylitis but also in the articular symptoms of reactive arthritis'8 and psoriatic arthritis, '9 20 and on the extra-articular symptoms of spondyloarthropathies such as psoriasis2' and uveitis.22
All these clinical trials were short term (three to six months) and were conducted in selected patients. Therefore to identify a subgroup of patients with spondyloarthropathy who might preferentially respond to sulphasalazine we retrospectively analysed the patients monitored in our department by comparing those who did and did not receive sulphasalazine and those who did and did not respond to treatment. In the group of patients who received sulphasalazine the long term effect of the drug was evaluated by using life table analysis to calculate the percentage of patients receiving treatment after some time.
Patients and methods
The files of all inpatients or outpatients consulting two of the authors (BA and MD) in the department ofrheumatology of Cochin Hospital in the period 1982-91 with a diagnosis of spondyloarthropathy were examined. All the patients who met the criteria for spondyloarthropathy3 4 were selected for study.
The basic disease related information was derived from the inpatient and outpatient files and consisted of the following: age, sex, HLA-B27 positivity, subgroup ofspondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive arthritis, arthritis related to inflammatory bowel disease, undifferentiated spondyloarthropathy), the rheumatological manifestations of spondyloarthropathy (axial disease, peripheral disease, enthesiopathy), the extra-articular features (uveitis, psoriasis, inflammatory bowel disease), severity of the spondyloarthropathy (hip disease, erosive arthritis), and treatment given.
For the patients who had received sulphasalazine the following parameters were noted: time of start of treatment relative to the onset of disease, duration of treatment, efficacy variables at entry and at the last visit (including night wakings due to pain, presence of morning stiffness, erythrocyte sedimentation rate (mm treatment over a six month period (59 patients) and a non-responder was defined as a patient who discontinued treatment because ofinefficacy between the fourth and sixth month (19 patients 
